Pulmatrix (PULM) Stock: Buy, Sell, or Hold?
PULM - Pulmatrix, Inc. Common Stock
$1.41
-0.05 (-3.42%)
▼
5d:
+3.68%
30d:
-11.88%
90d:
+2.92%
BUY
HIGH Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 15, 2026
Get Alerted When PULM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PULM shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: PULM shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: PULM is currently trading at $1.41, which is considered oversold relative to its 30-day fair value range of $1.44 to $1.60.
Technical Outlook: Technically, PULM is in a uptrend. Immediate support is located at $1.36, while resistance sits at $1.66. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: PULM scores 79/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.00 (+609.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PULM is in a uptrend. Immediate support is located at $1.36, while resistance sits at $1.66. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: PULM scores 79/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $10.00 (+609.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.44 -
$1.60
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (79/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 609.2% below Wall St target ($10.00)
- BULLISH: Bottoming setup score 79/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.44 -
$1.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.36
Resistance Level
$1.66
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Wall Street Target
$10.00
(+609.2%)
Revenue Growth (YoY)
-99.9%
Share & Embed Analysis
Last updated: September 13, 2026 3:06 PM ET
Data refreshes hourly during market hours. Next update: 4:06 PM
Data refreshes hourly during market hours. Next update: 4:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PULM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
